- Home
- ATNM vs FLYX Comparison
ATNM vs FLYX Comparison
Compare ATNM & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- FLYX
- Stock Information
- Founded
- ATNM 2000
- FLYX 2015
- Country
- ATNM United States
- FLYX United States
- Employees
- ATNM N/A
- FLYX N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- FLYX Blank Checks
- Sector
- ATNM Health Care
- FLYX Finance
- Exchange
- ATNM Nasdaq
- FLYX Nasdaq
- Market Cap
- ATNM 51.5M
- FLYX 54.1M
- IPO Year
- ATNM N/A
- FLYX N/A
- Fundamental
- Price
- ATNM $1.52
- FLYX $2.63
- Analyst Decision
- ATNM Strong Buy
- FLYX
- Analyst Count
- ATNM 3
- FLYX 0
- Target Price
- ATNM $4.67
- FLYX N/A
- AVG Volume (30 Days)
- ATNM 246.6K
- FLYX 14.1K
- Earning Date
- ATNM 08-04-2025
- FLYX 08-13-2025
- Dividend Yield
- ATNM N/A
- FLYX N/A
- EPS Growth
- ATNM N/A
- FLYX N/A
- EPS
- ATNM N/A
- FLYX N/A
- Revenue
- ATNM N/A
- FLYX $335,427,000.00
- Revenue This Year
- ATNM N/A
- FLYX $28.47
- Revenue Next Year
- ATNM N/A
- FLYX $22.44
- P/E Ratio
- ATNM N/A
- FLYX N/A
- Revenue Growth
- ATNM N/A
- FLYX 5.38
- 52 Week Low
- ATNM $1.03
- FLYX $1.79
- 52 Week High
- ATNM $8.64
- FLYX $5.19
- Technical
- Relative Strength Index (RSI)
- ATNM 42.39
- FLYX 42.81
- Support Level
- ATNM $1.41
- FLYX $2.77
- Resistance Level
- ATNM $1.95
- FLYX $2.80
- Average True Range (ATR)
- ATNM 0.13
- FLYX 0.23
- MACD
- ATNM -0.04
- FLYX -0.04
- Stochastic Oscillator
- ATNM 6.54
- FLYX 15.06
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.